Literature DB >> 30747487

Microparticles in systemic sclerosis: Potential pro-inflammatory mediators and pulmonary hypertension biomarkers.

Matthew R Lammi1,2, Lesley Ann Saketkoo2,3, Samuel C Okpechi4,5, Mohamed A Ghonim4,6, Dorota Wyczechowska4, Natalie Bauer7, Kusma Pyakurel4, Saito Saito2,3, Bennett P deBoisblanc1,2, A Hamid Boulares4.   

Abstract

BACKGROUND AND
OBJECTIVE: Endothelial microparticles (EMP) are submicron vesicles released from endothelial cells. We aimed to determine the utility of EMP as biomarkers of pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc) patients and the pathogenic role of microparticles (MP) in vascular inflammation.
METHODS: Levels of EMP (CD144+, CD31+, CD62E+ and CD143+) were compared between three groups (10 SSc patients with PAH, 10 SSc patients without pulmonary hypertension (no-PH) and 10 healthy age- and sex-matched controls). Human pulmonary artery endothelial cells (HPAEC) were exposed in vitro to MP obtained from SSc patients or healthy controls, and levels of cytokines and inflammatory adhesion molecules were compared.
RESULTS: CD144+ EMP were significantly higher in the SSc-PAH group compared to either the SSc-no PH or healthy controls (diagnostic accuracy 80%, P = 0.02). Compared to controls, SSc patients had higher CD31+/CD62E+ ratios, indicating larger contributions of apoptosis to EMP release (P = 0.04). Patients with limited SSc had significantly higher levels of CD143+ EMP compared to those with diffuse subtype (P = 0.008). When HPAEC were exposed to MP from SSc patients, there was a significant increase in inflammatory cytokines and adhesion molecules. Interestingly, exposure to healthy control MP caused a reduction in inflammatory markers.
CONCLUSION: EMP (particularly CD144+) are promising biomarkers of PAH in SSc but require further study. MP isolated from SSc patients induced an increase in endothelial cell inflammation and may be an important pathogenic factor in SSc.
© 2019 Asian Pacific Society of Respirology.

Entities:  

Keywords:  biomarkers; cardiovascular; cytokines and inflammatory mediators; respiratory; scleroderma

Mesh:

Substances:

Year:  2019        PMID: 30747487      PMCID: PMC6579687          DOI: 10.1111/resp.13500

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  42 in total

1.  Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis.

Authors:  Joaquin J Jimenez; Wenche Jy; Lucia M Mauro; Carl Soderland; Lawrence L Horstman; Yeon S Ahn
Journal:  Thromb Res       Date:  2003-02-15       Impact factor: 3.944

2.  The association between endothelial microparticles and inflammation in patients with systemic sclerosis and Raynaud's phenomenon as detected by functional imaging.

Authors:  Christian Jung; Karl Drummer; Peter Oelzner; Hans R Figulla; Joachim Boettcher; Marcus Franz; Stefan Betge; Martin Foerster; Gunter Wolf; Alexander Pfeil
Journal:  Clin Hemorheol Microcirc       Date:  2015       Impact factor: 2.375

3.  Increased frequency of interleukin 4 producing CD4+ and CD8+ cells in peripheral blood from patients with systemic sclerosis.

Authors:  J Tsuji-Yamada; M Nakazawa; M Minami; T Sasaki
Journal:  J Rheumatol       Date:  2001-06       Impact factor: 4.666

4.  Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma.

Authors:  B W Needleman; F M Wigley; R W Stair
Journal:  Arthritis Rheum       Date:  1992-01

5.  Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach.

Authors:  D Mukerjee; D St George; B Coleiro; C Knight; C P Denton; J Davar; C M Black; J G Coghlan
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

Review 6.  Endothelial adherens junctions at a glance.

Authors:  Elisabetta Dejana; Fabrizio Orsenigo
Journal:  J Cell Sci       Date:  2013-06-18       Impact factor: 5.285

7.  An investigation of the inflammatory cytokine and chemokine network in systemic sclerosis.

Authors:  Veronica Codullo; Helen M Baldwin; Mark D Singh; Alasdair R Fraser; Catherine Wilson; Ashley Gilmour; Axel J Hueber; Claudia Bonino; Iain B McInnes; Carlomaurizio Montecucco; Gerard J Graham
Journal:  Ann Rheum Dis       Date:  2011-02-01       Impact factor: 19.103

8.  PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4(+) T cell function.

Authors:  Mohamed A Ghonim; Kusma Pyakurel; Salome V Ibba; Amir A Al-Khami; Jeffrey Wang; Paulo Rodriguez; Hamada F Rady; Ali H El-Bahrawy; Matthew R Lammi; Moselhy S Mansy; Kamel Al-Ghareeb; Alistair Ramsay; Augusto Ochoa; Amarjit S Naura; A Hamid Boulares
Journal:  J Transl Med       Date:  2015-07-14       Impact factor: 5.531

9.  Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice.

Authors:  Laurent Savale; Ly Tu; Dominique Rideau; Mohamed Izziki; Bernard Maitre; Serge Adnot; Saadia Eddahibi
Journal:  Respir Res       Date:  2009-01-27

10.  Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study.

Authors:  J Gerry Coghlan; Christopher P Denton; Ekkehard Grünig; Diana Bonderman; Oliver Distler; Dinesh Khanna; Ulf Müller-Ladner; Janet E Pope; Madelon C Vonk; Martin Doelberg; Harbajan Chadha-Boreham; Harald Heinzl; Daniel M Rosenberg; Vallerie V McLaughlin; James R Seibold
Journal:  Ann Rheum Dis       Date:  2013-05-18       Impact factor: 19.103

View more
  5 in total

Review 1.  A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc.

Authors:  Lesley Ann Saketkoo; Tracy Frech; Cecília Varjú; Robyn Domsic; Jessica Farrell; Jessica K Gordon; Carina Mihai; Nora Sandorfi; Lee Shapiro; Janet Poole; Elizabeth R Volkmann; Monika Lammi; Kendra McAnally; Helene Alexanderson; Henrik Pettersson; Faye Hant; Masataka Kuwana; Ami A Shah; Vanessa Smith; Vivien Hsu; Otylia Kowal-Bielecka; Shervin Assassi; Maurizio Cutolo; Cristiane Kayser; Victoria K Shanmugam; Madelon C Vonk; Kim Fligelstone; Nancy Baldwin; Kerri Connolly; Anneliese Ronnow; Beata Toth; Maureen Suave; Sue Farrington; Elana J Bernstein; Leslie J Crofford; László Czirják; Kelly Jensen; Monique Hinchclif; Marie Hudson; Matthew R Lammi; Jennifer Mansour; Nadia D Morgan; Fabian Mendoza; Mandana Nikpour; John Pauling; Gabriela Riemekasten; Anne-Marie Russell; Mary Beth Scholand; Elise Seigart; Tatiana Sofia Rodriguez-Reyna; Laura Hummers; Ulrich Walker; Virginia Steen
Journal:  Best Pract Res Clin Rheumatol       Date:  2021-09-15       Impact factor: 4.991

2.  Elevated circulating endothelial microparticles (EMPs) in prepubertal children born preterm.

Authors:  Panagiota Markopoulou; Eleni Papanikolaou; Sofia Loukopoulou; Paraskevi Galina; Ioannis Papassotiriou; Tania Siahanidou
Journal:  Pediatr Res       Date:  2021-07-20       Impact factor: 3.953

Review 3.  An Overview of Circulating Pulmonary Arterial Hypertension Biomarkers.

Authors:  Joana Santos-Gomes; Inês Gandra; Rui Adão; Frédéric Perros; Carmen Brás-Silva
Journal:  Front Cardiovasc Med       Date:  2022-07-14

4.  Elevated Circulatory Levels of Microparticles Are Associated to Lung Fibrosis and Vasculopathy During Systemic Sclerosis.

Authors:  Damien Leleu; Emeline Levionnois; Paoline Laurent; Estibaliz Lazaro; Christophe Richez; Pierre Duffau; Patrick Blanco; Vanja Sisirak; Cecile Contin-Bordes; Marie-Elise Truchetet
Journal:  Front Immunol       Date:  2020-10-23       Impact factor: 7.561

Review 5.  The changing face of pulmonary hypertension diagnosis: a historical perspective on the influence of diagnostics and biomarkers.

Authors:  Jenny L Hewes; Ji Young Lee; Karen A Fagan; Natalie N Bauer
Journal:  Pulm Circ       Date:  2020-02-04       Impact factor: 3.017

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.